Articles

Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, break down the misconceptions that patients with multiple myeloma may have about the different treatment regimens and how those misconceptions can affect their views on treatment adherence. Read More ›

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy

By Jonathan Wesley Riess, MD, MS

NSCLC

Supplements

Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC). Read More ›

Liquid Biopsy in Advanced NSCLC Expedites Tumor Screening and Treatment Initiation

Lung Cancer

Web Exclusives

Liquid biopsy improves turnaround time for molecular genotyping, but further improvement in next-generation sequencing is recommended. Read More ›

Nephrotoxicity Risk Factors with Use of Pemetrexed in Patients with NSCLC

Lung Cancer

Web Exclusives

A recent study identified several risk factors associated with the development of nephrotoxicity when using pemetrexed in patients with non–small-cell lung cancer. Read More ›

Examining the Nutritional Status and Treatment Protocols of Patients with NSCLC

Lung Cancer

Web Exclusives

Researchers identified an association between nutritional status, treatment protocols, and survival in patients with advanced non–small-cell lung cancer. Read More ›

PD-1/PD-L1 Monoclonal Antibody Use Is Effective in Young and Elderly Patients with NSCLC

Lung Cancer

Web Exclusives

Recently released study findings on PD-1/PD-L1 immunotherapy in young and elderly patients with metastatic NSCLC found the treatment is safe and effective in both patient cohorts. Read More ›

IWTI Multiple Myeloma

Breaking Down Barriers to Treatment Adherence for Patients with Multiple Myeloma

By Charise Gleason, MSN, NP-C, AOCNP; Nikki Barkett, RN, BSN, OCN

Interview with the Innovators

Videos

Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, discuss the multiple potential barriers to treatment adherence that some patients with multiple myeloma may face in their cancer journey and how they utilize some of their best practices to keep patients on therapy. Read More ›

IWTI Multiple Myeloma

Managing Quality-of-Life Issues for Patients with Multiple Myeloma

By Charise Gleason, MSN, NP-C, AOCNP; Nikki Barkett, RN, BSN, OCN

Interview with the Innovators

Videos

Clinicians spend a lot of time focusing on treatment plans for patients with multiple myeloma. However, quality-of-life issues are just as important to patients. Please join Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, as they share their approach to helping patients cope and maintain an acceptable quality of life. Read More ›

Baylor Scott & White Charles A. Sammons Cancer Center: Committed to Excellence

Cancer Center Profile

TON - April 2022 Vol 15, No 2

The Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX, is an integral part of Baylor University Medical Center, a nationally recognized, faith-based, not-for-profit hospital that serves more than 300,000 patients each year. Read More ›

Elacestrant Elicits Positive Outcomes in Patients with Metastatic Breast Cancer Who Have Progressed on Previous Endocrine Therapy

By Patricia Stewart

Breast Cancer

TON - April 2022 Vol 15, No 2

The investigational oral selective estrogen receptor degrader (SERD) elacestrant (RAD1901) significantly reduced the risk for death or disease progression and improved progression-free survival (PFS) compared with standard-of-care (SOC) endocrine therapy in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who had progressed on prior endocrine and targeted therapies, according to results of the phase 3 EMERALD clinical trial. Read More ›

Articles

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Articles

Page 41 of 376

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: